, Volume 63, Issue 3, pp 293–296 | Cite as

The effect of propranolol treatment in schizophrenia on CSF amine metabolites and prolactin

  • R. H. Belmaker
  • R. P. Ebstein
  • H. Dasberg
  • A. Levy
  • G. Sedvall
  • H. M. Van Praag
Original Investigations


Recent reports have suggested that high doses of propranolol may be an effective treatment in schizophrenia. To determine whether such treatment has effects on cerebrospinal fluid (CSF) amine metabolites and prolactin similar to the effects of the neuroleptic drugs, we studied CSF from ten patients before and after propranolol therapy. The initial CSF sample was removed after a drug-free period and propranolol dosage was then increased over 1 week to 1000 mg daily in all ten patients. A second CSF sample was removed after 3 weeks of propranolol therapy. Propranolol levels and prolactin in CSF were measured by radioimmunoassay. Homovanillic acid, 5-hydroxyindoleacetic acid, and 3-methoxy-4-hydroxyphenylethylene glycol were measured by gas chromatography-mass spectrometry. Propranolol had no effect on the prolactin or amine metabolite concentrations. CSF propranolol levels averaged 40 ng/ml (range <1–78).

Key words

Propranolol Schizophrenia Cerebrospinal fluid Homovanillic acid 5-hydroxyindoleacetic acid 3-methoxy-4-hydroxyphenylethylene glycol 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alfredsson, G., Wiesel, F. A., Skett, P.: Levels of chlorpromazine and its active metabolites in rat brain and the relationship to central monoamine metabolism and prolactin secretion. Psychopharmacology 53, 13–17 (1977)Google Scholar
  2. Atsmon, A., Blum, I., Steiner, M., Latz, A., Wijsenbeek, H.: Further studies with propranolol in psychotic patients: Relation to initial psychiatric state, urinary catecholamines and 3-methoxy-4-hydroxyphenylglycol excretion. Psychopharmacologia (Berl.) 27, 249–254 (1972)Google Scholar
  3. Atsmon, A.: Early observations of the effect of propranolol on psychotic patients. Adv. Clin. Pharmacol. 12, 86–90 (1976)Google Scholar
  4. Belmaker, R. H., Ebstein, R. P., Biederman, J., Stern, R., Berman, M., Van Praag, H. M.: The effect of l-dopa and propranolol on human CSF cyclic nucleotides. Psychopharmacology 58, 307–310 (1978)Google Scholar
  5. Carlsson, A.: Antipsychotic drugs, neurotransmitters, and schizophrenia. Am. J. Psychiatry 135, 164–173 (1978)Google Scholar
  6. Gardos, G., Cole, J. O., Volicer, L., Orzack, M. H., Oliff, A. C.: A dose-response study of propranolol in chronic schizophrenics. Curr. Ther. Res. 15, 314–323 (1973)Google Scholar
  7. Gruen, P. H., Sachar, E. J., Langer, G., Altman, N., Leifer, M., Frantz, A., Halpern, F. S.: Prolactin responses to neuroleptics in normal and schizophrenic subjects. Arch. Gen. Psychiatry 35, 108–116 (1978)Google Scholar
  8. Hanssen, T., Heyden, T., Sundberg, I., Wetterberg, L., Eneroth, P.: Decrease in serum-prolactin after propranolol in schizophrenia. Lancet 1978I, 101–102Google Scholar
  9. Kawashima, K., Levy, A., Spector, S.: Stereo-specific radioimmunoassay for propranolol isomers. J. Pharmacol. Exp. Ther. 196, 517–523 (1976)Google Scholar
  10. Keller, H. H., Bartholini, G., Pletscher, A.: Increase of 3-methoxy-4-hydroxyphenylethylene glycol in rat brain by neuroleptic drugs. Eur. J. Pharmacol. 23, 183–186 (1973)Google Scholar
  11. Nasrallah, H. A., Freed, W. J., Rogol, A., Wyatt, R. J.: Propranolol and prolactin. Lancet 1977II, 1175Google Scholar
  12. Post, R. M., Goodwin, F. K.: Time-dependent effects of phenothiazines on dopamine turnover in psychiatric patients. Science 190, 488–489 (1975)Google Scholar
  13. Sedvall, G., Alfredsson, G., Bjerkenstedt, L., Eneroth, P., Fyro, B., Harnoyd, C., Wode-Helgodt, B.: Central biochemical correlates to antipsychotic drug action in man. In: The impact of biology on modern psychiatry, E. S. Gershon, R. H. Belmaker, M. Rosenbaum, S. S. Kety, eds., pp. 41–54. New York: Plenum 1977Google Scholar
  14. Shand, D. G.: Pharmacokinetic properties of the β-adrenergic receptor blocking drugs. Drugs 7, 39–47 (1974)Google Scholar
  15. Swahn, C. G., Sandgarde, B., Wiesel, F. A., Sedvall, G.: Simultaneous determination of the three major monoamine metabolites in brain tissue and body fluids by a mass fragmentographic method. Psychopharmacology 48, 147–151 (1976)Google Scholar
  16. Van Praag, H. M.: The significance of the cerebral dopamine metabolism in the pathogenesis and treatment of psychiatric disorders. In: The impact of biology on modern psychiatry, E. S. Gershon, R. H. Belmaker, M. Rosenbaum, S. S. Kety, eds., pp. 1–26. New York: Plenum 1977Google Scholar
  17. Weinstock, M., Speiser, Z., Ashkenazi, R.: Biochemical and pharmacological studies on an animal model of hyperactivity states. In: The impact of biology on modern psychiatry, E. S. Gershon, R. H. Belmaker, M. Rosenbaum, S. S. Kety, eds., pp. 149–162. New York: Plenum 1977aGoogle Scholar
  18. Weinstock, M., Weiss, C., Gitter, S.: Blockade of 5-hydroxytryptamine receptors in the central nervous system by beta-adrenoceptor antagonists. Neuropharmacology 16, 273–276 (1977b)Google Scholar
  19. Wiesel, F. A.: Effects of high dose propranolol treatment on dopamine and norepinephrine metabolism in regions of rat brain. Neurosci. Letters. 2, 35–38 (1976)Google Scholar
  20. Wode-Helgodt, B., Fyro, B., Gullberg, B., Sedvall, G.: Effect of chlorpromazine treatment on monoamine metabolite levels in cerebrospinal fluid of psychotic patients. Acta Psychiatr. Scand. 56, 129–142 (1977a)Google Scholar
  21. Wode-Helgodt, B., Eneroth, P., Fyro, B., Gullberg, B., Sedvall, G.: Effect of chlorpromazine treatment on prolactin levels in cerebrospinal fluid and plasma of psychotic patients. Acta Psychiatr. Scand. 56, 280–293 (1977b)Google Scholar
  22. Yorkston, N. J., Gruzelier, J. H., Zaki, S. A., Hollander, D., Pitcher, D. R., Sergeant, H. G. S.: Propranolol as an adjunct to the treatment of schizophrenia. Lancet 1977I, 575–578Google Scholar
  23. Yorkston, N. J., Zaki, S. A., Malik, M. K. U., Morrison, R. C., Havard, C. W. H.: Propranolol in the control of schizophrenic symptoms. Br. Med. J. 1974IV, 633–635Google Scholar

Copyright information

© Springer-Verlag 1979

Authors and Affiliations

  • R. H. Belmaker
    • 1
  • R. P. Ebstein
    • 1
  • H. Dasberg
    • 1
  • A. Levy
    • 2
  • G. Sedvall
    • 3
  • H. M. Van Praag
    • 4
  1. 1.Jerusalem Mental Health Center-Ezrath NashimJerusalemIsrael
  2. 2.Israol Institute for Biological ResearchNess-ZionaIsrael
  3. 3.Department of PsychiatryKarolinska HospitalStockholmSweden
  4. 4.Department of PsychiatryUniversity HospitalUtrechtThe Netherlands

Personalised recommendations